Edaravone for amyotrophic lateral sclerosis: barriers to access and lifeboat ethics

scientific article published on 01 March 2020

Edaravone for amyotrophic lateral sclerosis: barriers to access and lifeboat ethics is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1503/CMAJ.191236
P932PMC publication ID7101182
P698PubMed publication ID32392516

P2093author name stringLorne Zinman
Ari Breiner
Pierre R Bourque
P2860cites workConfirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patientsQ34699979
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trialQ38776278
Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicentersQ44418044
A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study GroupQ72759362
P433issue12
P921main subjectamyotrophic lateral sclerosisQ206901
edaravoneQ335099
P304page(s)E319-E320
P577publication date2020-03-01
P1433published inCanadian Medical Association JournalQ5030320
P1476titleEdaravone for amyotrophic lateral sclerosis: barriers to access and lifeboat ethics
P478volume192

Search more.